Breaking News, Collaborations & Alliances

CMC Biologics, RuiYi in MAb Development Pact

CMC will use CHEF1 system for cell line development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CMC Biologics has entered an agreement with RuiYi, Inc. to develop a cell line for RYI-008, an anti-IL-6 monoclonal antibody. CMC will use its CHEF1 high-productivity expression plasmid for the cell line development to optimize cell growth and protein expression in a rapid time frame. Financial terms were not disclosed.   “We are excited to work with CMC Biologics, a global contract manufacturing organization known for its technical excellence in biopharmaceutical development and cGMP manu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters